Is Medicamen Organ. overvalued or undervalued?

As of 10 November 2025, the valuation grade for Medicamen Organ. has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 10.23, an EV to EBIT of 8.80, and a ROCE of 12.71%.
In comparison to its peers, Medicamen Organ. stands out with a PE ratio that is significantly lower than Sun Pharma's 35.15 and Divi's Lab's 71.55, both of which are categorized as expensive. Additionally, its EV to EBITDA ratio of 7.63 is more favorable than the industry average, suggesting a reasonable valuation relative to its earnings potential. Recent stock performance has been underwhelming, with a year-to-date return of -46.94%, contrasting sharply with the Sensex's gain of 8.16%, further emphasizing the current valuation context.